IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest™ in breast carcinoma

Background: Her2 (c-erbB-2/neu) overexpression in breast carcinoma predicts response to the anti-Her2 monoclonal antibody, trastuzumab, and is associated with a poor prognosis. When considering patients for trastuzumab treatment, Her2 protein expression is measured by imunohistochemistry (IHC) and,...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Ainsworth, R, Bartlett, J M S, Going, J J, Mallon, E A, Forsyth, A, Richmond, J, Angerson, W, Watters, A, Dunne, B
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Copyright 2005 Journal of Clinical Pathology 2005
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC1770743/
https://ncbi.nlm.nih.gov/pubmed/16189156
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jcp.2004.021576
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller